---
title: "Cerus Corporation (CERS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CERS.US.md"
symbol: "CERS.US"
name: "Cerus Corporation"
industry: "Health Care Supplies"
datetime: "2026-05-20T12:04:27.928Z"
locales:
  - [en](https://longbridge.com/en/quote/CERS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CERS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CERS.US.md)
---

# Cerus Corporation (CERS.US)

## Company Overview

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment.

| Item | Detail |
|------|--------|
| Industry | Health Care Supplies |
| Exchange | US Market |
| Website | [www.cerus.com](https://www.cerus.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: C (0.47)**

**Industry**: Health Care Supplies

| Metric | Value |
|--------|-------|
| Industry Ranking | 20 / 45 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 16.97% |  |
| Net Profit YoY | 49.60% |  |
| P/B Ratio | 8.01 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 540996229.80 |  |
| Revenue | 216555000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -15.52% | E |
| Profit Margin | -4.41% | D |
| Gross Margin | 51.98% | B |
| Revenue YoY | 16.97% | B |
| Net Profit YoY | 49.60% | B |
| Total Assets YoY | 7.80% | B |
| Net Assets YoY | 21.41% | A |
| Cash Flow Margin | -27.56% | E |
| OCF YoY | 16.97% | B |
| Turnover | 1.01 | A |
| Gearing Ratio | 69.37% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Cerus Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "16.97%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "49.60%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "8.01",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "540996229.80",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "216555000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-15.52%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-4.41%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "51.98%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "16.97%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "49.60%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "7.80%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "21.41%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-27.56%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "16.97%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "1.01",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "69.37%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -56.65 | 43/45 | - | - | - |
| PB | 8.01 | 34/45 | 6.72 | 5.39 | 4.62 |
| PS (TTM) | 2.50 | 26/45 | 2.07 | 1.60 | 1.38 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Essilor (ESLOY.US) | B | B | C | B | B | B |
| 02 | HOYA Corporation (HOCPY.US) | A | C | B | A | B | B |
| 03 | Align (ALGN.US) | B | C | B | B | C | B |
| 04 | Lantheus (LNTH.US) | A | C | B | C | C | B |
| 05 | Merit Medical (MMSI.US) | B | B | B | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-01T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.70 |
| Highest Target | 5.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CERS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CERS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CERS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CERS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**